[go: up one dir, main page]

MX2013002694A - Derivados de tetrahidroquinolina usados como activadores de proteina cinasa activada por monofosfato de adenosina. - Google Patents

Derivados de tetrahidroquinolina usados como activadores de proteina cinasa activada por monofosfato de adenosina.

Info

Publication number
MX2013002694A
MX2013002694A MX2013002694A MX2013002694A MX2013002694A MX 2013002694 A MX2013002694 A MX 2013002694A MX 2013002694 A MX2013002694 A MX 2013002694A MX 2013002694 A MX2013002694 A MX 2013002694A MX 2013002694 A MX2013002694 A MX 2013002694A
Authority
MX
Mexico
Prior art keywords
derivatives used
tetrahydroquinoline derivatives
ampk activators
sup
ampk
Prior art date
Application number
MX2013002694A
Other languages
English (en)
Inventor
Lichun Feng
Guolong Wu
Mengwei Huang
Yongfu Liu
Mingwei Zhou
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2013002694A publication Critical patent/MX2013002694A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un compuesto de la Fórmula (I), o una sal o éster farmacéuticamente aceptable del mismo, en donde R1 a R7 tienen el significado dado en la reivindicación 1, puede ser utilizado como un medicamento.
MX2013002694A 2010-10-20 2011-10-17 Derivados de tetrahidroquinolina usados como activadores de proteina cinasa activada por monofosfato de adenosina. MX2013002694A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2010077907 2010-10-20
PCT/EP2011/068053 WO2012052372A1 (en) 2010-10-20 2011-10-17 Tetrahydroquinoline derivatives used as ampk activators

Publications (1)

Publication Number Publication Date
MX2013002694A true MX2013002694A (es) 2013-05-22

Family

ID=44860331

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013002694A MX2013002694A (es) 2010-10-20 2011-10-17 Derivados de tetrahidroquinolina usados como activadores de proteina cinasa activada por monofosfato de adenosina.

Country Status (10)

Country Link
US (1) US8546427B2 (es)
EP (1) EP2630124B1 (es)
JP (1) JP6104807B2 (es)
KR (1) KR101854485B1 (es)
BR (1) BR112013009640A2 (es)
CA (1) CA2814594C (es)
ES (1) ES2527194T3 (es)
MX (1) MX2013002694A (es)
RU (1) RU2615758C2 (es)
WO (1) WO2012052372A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
JP6064062B2 (ja) 2013-03-15 2017-01-18 ファイザー・インク Ａｍｐｋを活性化させるインダゾール化合物
WO2015103480A1 (en) 2014-01-02 2015-07-09 Massachusetts Eye & Ear Infirmary Treating ocular neovascularization
US20180290979A1 (en) * 2015-04-30 2018-10-11 Kyoto University Composition having compound accelerating phosphorylation of ampk as effective component
CN116718691B (zh) * 2023-06-01 2025-09-09 杭州国瑞生物科技有限公司 一种利用hplc测定2,4,6-三甲基苯磺酰氯色谱纯度的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4523273B2 (ja) * 2001-07-02 2010-08-11 ナームローゼ・フエンノートチヤツプ・オルガノン テトラヒドロキノリン誘導体
DE10236910A1 (de) * 2002-08-12 2004-03-11 Grünenthal GmbH Substituierte 1,2,3,4-Tetrahydrochinolinderivate
WO2004072041A1 (en) * 2003-02-12 2004-08-26 Care X S.A. Tetrahydroquinolines as agonists of liver- x receptors
US7138412B2 (en) 2003-03-11 2006-11-21 Bristol-Myers Squibb Company Tetrahydroquinoline derivatives useful as serine protease inhibitors
RU2375354C2 (ru) * 2003-12-20 2009-12-10 Мерк Патент Гмбх Производные 2-(гетеро)арил-замещенных тетрагидрохинолинов
US8344137B2 (en) * 2010-04-14 2013-01-01 Hoffman-La Roche Inc. 3,3-dimethyl tetrahydroquinoline derivatives

Also Published As

Publication number Publication date
KR101854485B1 (ko) 2018-05-03
CA2814594C (en) 2018-06-12
EP2630124B1 (en) 2014-11-19
US8546427B2 (en) 2013-10-01
EP2630124A1 (en) 2013-08-28
US20120101127A1 (en) 2012-04-26
JP6104807B2 (ja) 2017-03-29
BR112013009640A2 (pt) 2016-07-12
WO2012052372A1 (en) 2012-04-26
KR20140002644A (ko) 2014-01-08
ES2527194T3 (es) 2015-01-21
RU2013120137A (ru) 2014-11-27
JP2013541551A (ja) 2013-11-14
CA2814594A1 (en) 2012-04-26
RU2615758C2 (ru) 2017-04-11

Similar Documents

Publication Publication Date Title
PH12012501772A1 (en) N-(imidazopyrimidin-7-yl)-heteroarylamide derivatives and their use as pde10a inhibitors
MX2012009186A (es) Pirrolidina-2-carboxamidas sustituidas.
PH12012501029A1 (en) Spiroindolinone pyrrolidines
IN2012DN03337A (es)
MY183312A (en) Pharmaceutical formulation
MX2010005824A (es) Derivados de aminotiazol.
MD20140084A2 (en) New indolizine derivatives, method for preparing same and pharmaceutical compositions containing same
PH12015501412A1 (en) SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND MEDICINAL USE THEREOF AS HIV INTEGRASE INHIBITOR
MX2014014229A (es) Pirrolidina-2-carboxamidas sustituidas.
IN2012DN00765A (es)
MX2012000414A (es) Derivados piridin-4-ilo.
MX2011008176A (es) Derivados de 3,3'-espiroindolinona como agentes anticancerigenos.
TW200801000A (en) Spiroindolinone derivatives
PH12013500942A1 (en) Triazolopyridine compounds
MX2012007536A (es) Derivados de heteroarilo que contienen nitrogeno.
MY165918A (en) Heterocyclic sulfonamides, uses and pharmaceutical compositions thereof
UA114656C2 (uk) Похідні піридину
UA97821C2 (en) Cyclized derivatives as eg-5 inhibitors
PH12014500499A1 (en) Triazolopyridine compounds as pde10a inhibitors
PH12015502429A1 (en) Dicarboxylic acid compound
MX2011008360A (es) Derivados de piridazinona sustituida con heteroarilo.
MX2010005164A (es) Derivados de bencimidazol y su uso como agonistas del receptor x de farnesoide.
MX2013002620A (es) Novedosas n-hidroxi-benzamidas para el tratamiento del cancer.
MX2013002694A (es) Derivados de tetrahidroquinolina usados como activadores de proteina cinasa activada por monofosfato de adenosina.
MY161749A (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use

Legal Events

Date Code Title Description
FG Grant or registration